利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.018 秒)

    A SUPRABASAL BREAST CELL LINE WITH STEM CELL PROPERTIES
    2.
    发明公开
    A SUPRABASAL BREAST CELL LINE WITH STEM CELL PROPERTIES 审中-公开
    SUPRABASAL BRUSTZELLLINIE MIT STAMZELLEN EIGENSCHAFTEN

    公开(公告)号：EP1465984A1

    公开(公告)日：2004-10-13

    申请号：EP03704437.7

    申请日：2003-01-16

    申请人： Kobenhavns Universitet

    发明人： PETERSEN, Lone, Ronnov-Jessen ,  PETERSEN, Ole, William ,  GODJONSSON, Thorarinn ,  VILLADSEN, René ,  BISSELL, Mona, J.

    IPC分类号： C12N5/08 ,  A61K35/12 ,  A61K48/00 ,  G01N33/50

    CPC分类号： C12N5/0631 ,  A61K35/12 ,  C12N2503/02 ,  C12N2510/00 ,  C12N2510/04 ,  G01N33/5011 ,  G01N33/5017 ,  G01N2333/4742

    摘要： A method for isolating cells which have a suprabasal position and expresses epithelial specific antigen but no sialomucin is provided. The isolated cells are shown to share many of the properties expected of a mammary gland stem cell. Three permanent cell lines that are capable of proliferating and capable of differentiating into cells of mammary gland luminal epithelial and myoepithelial cell lineages were established. Such cells form elaborate branching structures resembling uncultured terminal duct lobular units both by morphology and marker expression both in vitro and in vivo. Evidence is provided that these keratin K19 expressing cells most probably is the cells in which breast cancer arises. Thus they constitute a model not only for the developing breast, but also for the development of breast cancer. Also disclosed are the uses of such isolated cells or the cell lines as a model system of the mammary gland for pharmacological studies and their uses in tissue repair or transplantation.

    摘要翻译： 提供了一种分离具有上基础位置并表达上皮特异性抗原但不含唾液酸粘蛋白的细胞的方法。 分离的细胞被证明具有乳腺干细胞预期的许多性质。 建立了能够增殖并能分化成乳腺腔上皮细胞和肌上皮细胞谱系细胞的三种永久性细胞系。 这样的细胞通过体外和体内的形态学和标志物表达形成类似于未培养的末端管小叶单位的精细分枝结构。 证据表明这些角蛋白K19表达细胞最可能是乳腺癌发生的细胞。 因此，它们不仅是发展中的乳房，而且也是乳腺癌发展的模型。 还公开了这种分离的细胞或细胞系作为乳腺的模型系统用于药理学研究及其在组织修复或移植中的用途的用途。

    COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY-ASSOCIATED MALARIA
    3.
    发明公开
    COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY-ASSOCIATED MALARIA 有权
    连接进行诊断和治疗妊娠相关疟疾有用

    公开(公告)号：EP1590368A1

    公开(公告)日：2005-11-02

    申请号：EP03767493.4

    申请日：2003-12-30

    申请人： Kobenhavns Universitet

    发明人： THEANDER, Thor, Grundtvig ,  SALANTI, Ali ,  HVIID, Lars ,  STAALSÖ , Trine ,  JENSEN, Anja, Tatiana, Ramstedt ,  LAVSTSEN, Thomas ,  DAHLBÄCK, Madeleine

    IPC分类号： C07K14/445 ,  A61K39/015 ,  G01N33/569 ,  C12Q1/68 ,  A61K31/7088 ,  C07K16/20

    CPC分类号： C07K16/205 ,  A61K38/00 ,  Y10S435/975

    摘要： The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic for the pathogenesis of pregnancy associated malaria (PAM). Accordingly, The invention provides the use compounds that are related to VAR2CSA polypeptides and var2csa nucleic acid molecules as medicaments, as well as it provides pharmaceutical compositions, in particular immunological compositions and vaccines, hereunder nucleotide-based vaccines comprising these compounds. In addition, the invention provides the use of the compounds mentionedfor the manufacture of compositions, such as immunogenic compositions. Other aspects of the invention relates to methods of treatment and prevention of pregnancy associated malaria wherein these methods are based on the nucleic acid molecules and polypeptides of the invention. As these compounds can also be used as biotechnological tools the invention provides in vitro diagnostic methods and kits comprising reagents and IgGs/antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR2CSA dependent adhesion to CSA and agent capable of interacting with VAR2CSA. Finally, a method for identifying polypeptides, which will induce a specific IgG/antibody response upon administration to a subject is provided by the invention.